Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma

Marina Buzzi, D. Granchi, G. Bacci, S. Ferrari, M. Fogli, F. Fiori, C. Tarabusi, T. Venezian, A. Pederzoli, A. Pizzoferrato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The introduction of aggressive chemotherapy in the treatment of osteosarcoma has improved the long-term outcome for these patients. With the increasing aggressiveness of chemotherapy protocols, hematopoietic growth factors have emerged as useful adjuncts involving, in some cases, rescue by peripheral blood stem cell (PBSC) infusion to assist faster recovery and maintain relative dose intensity. To evaluate the number of PBSCs needed, we analyzed the number of CD34+ cells and hematopoietic progenitor cells in the peripheral blood of 16 patients with osteoblastic, condroblastic and fibroblastic osteosarcoma enrolled in an Istituto Ortopedico Rizzoli- Scandinavian Sarcoma Group (IOR-SSG) pilot study, consisting of two cycles of preoperative high dose chemotherapy. The blood samples were studied at different times. The CD34+ cells were analyzed by flow cytometry and the hematopoietic progenitor cells were analyzed by tissue culture clonogenic assay. In comparing the two courses of chemotherapy, we observed that modification of the mean values of WBC, CD34+ and CFU-GM were very similar. The second course of chemotherapy seemed to induce greater hematological toxicity. All three parameters showed good correlation. The results demonstrated that the best time to collect PBSC by means of leukapheresis is post G-CSF used as rescue after ifosfamide treatment. We verified the ability of G-CSF to mobilize PBSCs in patients with osteosarcoma through cytofluorimetric analysis of CD34+ cells and their clonogenic capability. Moreover, during this preoperative treatment, we identified the best time to collect a sufficient number of PBSCs, that is after 9-10 days of G-CSF treatment following the first cycle of ifosfamide.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalJournal of Chemotherapy
Volume11
Issue number4
Publication statusPublished - 1999

Fingerprint

Granulocyte Colony-Stimulating Factor
Osteosarcoma
Drug Therapy
Ifosfamide
Hematopoietic Stem Cells
Leukapheresis
Therapeutics
Granulocyte-Macrophage Progenitor Cells
Sarcoma
Intercellular Signaling Peptides and Proteins
Flow Cytometry
Cell Count
Peripheral Blood Stem Cells

Keywords

  • CD34
  • Clonogenic cells
  • Osteosarcoma
  • Peripheral blood stem cell

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. / Buzzi, Marina; Granchi, D.; Bacci, G.; Ferrari, S.; Fogli, M.; Fiori, F.; Tarabusi, C.; Venezian, T.; Pederzoli, A.; Pizzoferrato, A.

In: Journal of Chemotherapy, Vol. 11, No. 4, 1999, p. 293-300.

Research output: Contribution to journalArticle

Buzzi, M, Granchi, D, Bacci, G, Ferrari, S, Fogli, M, Fiori, F, Tarabusi, C, Venezian, T, Pederzoli, A & Pizzoferrato, A 1999, 'Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma', Journal of Chemotherapy, vol. 11, no. 4, pp. 293-300.
Buzzi, Marina ; Granchi, D. ; Bacci, G. ; Ferrari, S. ; Fogli, M. ; Fiori, F. ; Tarabusi, C. ; Venezian, T. ; Pederzoli, A. ; Pizzoferrato, A. / Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. In: Journal of Chemotherapy. 1999 ; Vol. 11, No. 4. pp. 293-300.
@article{3c0e56fd7a544bb7b9ca0ca4afac430f,
title = "Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma",
abstract = "The introduction of aggressive chemotherapy in the treatment of osteosarcoma has improved the long-term outcome for these patients. With the increasing aggressiveness of chemotherapy protocols, hematopoietic growth factors have emerged as useful adjuncts involving, in some cases, rescue by peripheral blood stem cell (PBSC) infusion to assist faster recovery and maintain relative dose intensity. To evaluate the number of PBSCs needed, we analyzed the number of CD34+ cells and hematopoietic progenitor cells in the peripheral blood of 16 patients with osteoblastic, condroblastic and fibroblastic osteosarcoma enrolled in an Istituto Ortopedico Rizzoli- Scandinavian Sarcoma Group (IOR-SSG) pilot study, consisting of two cycles of preoperative high dose chemotherapy. The blood samples were studied at different times. The CD34+ cells were analyzed by flow cytometry and the hematopoietic progenitor cells were analyzed by tissue culture clonogenic assay. In comparing the two courses of chemotherapy, we observed that modification of the mean values of WBC, CD34+ and CFU-GM were very similar. The second course of chemotherapy seemed to induce greater hematological toxicity. All three parameters showed good correlation. The results demonstrated that the best time to collect PBSC by means of leukapheresis is post G-CSF used as rescue after ifosfamide treatment. We verified the ability of G-CSF to mobilize PBSCs in patients with osteosarcoma through cytofluorimetric analysis of CD34+ cells and their clonogenic capability. Moreover, during this preoperative treatment, we identified the best time to collect a sufficient number of PBSCs, that is after 9-10 days of G-CSF treatment following the first cycle of ifosfamide.",
keywords = "CD34, Clonogenic cells, Osteosarcoma, Peripheral blood stem cell",
author = "Marina Buzzi and D. Granchi and G. Bacci and S. Ferrari and M. Fogli and F. Fiori and C. Tarabusi and T. Venezian and A. Pederzoli and A. Pizzoferrato",
year = "1999",
language = "English",
volume = "11",
pages = "293--300",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma

AU - Buzzi, Marina

AU - Granchi, D.

AU - Bacci, G.

AU - Ferrari, S.

AU - Fogli, M.

AU - Fiori, F.

AU - Tarabusi, C.

AU - Venezian, T.

AU - Pederzoli, A.

AU - Pizzoferrato, A.

PY - 1999

Y1 - 1999

N2 - The introduction of aggressive chemotherapy in the treatment of osteosarcoma has improved the long-term outcome for these patients. With the increasing aggressiveness of chemotherapy protocols, hematopoietic growth factors have emerged as useful adjuncts involving, in some cases, rescue by peripheral blood stem cell (PBSC) infusion to assist faster recovery and maintain relative dose intensity. To evaluate the number of PBSCs needed, we analyzed the number of CD34+ cells and hematopoietic progenitor cells in the peripheral blood of 16 patients with osteoblastic, condroblastic and fibroblastic osteosarcoma enrolled in an Istituto Ortopedico Rizzoli- Scandinavian Sarcoma Group (IOR-SSG) pilot study, consisting of two cycles of preoperative high dose chemotherapy. The blood samples were studied at different times. The CD34+ cells were analyzed by flow cytometry and the hematopoietic progenitor cells were analyzed by tissue culture clonogenic assay. In comparing the two courses of chemotherapy, we observed that modification of the mean values of WBC, CD34+ and CFU-GM were very similar. The second course of chemotherapy seemed to induce greater hematological toxicity. All three parameters showed good correlation. The results demonstrated that the best time to collect PBSC by means of leukapheresis is post G-CSF used as rescue after ifosfamide treatment. We verified the ability of G-CSF to mobilize PBSCs in patients with osteosarcoma through cytofluorimetric analysis of CD34+ cells and their clonogenic capability. Moreover, during this preoperative treatment, we identified the best time to collect a sufficient number of PBSCs, that is after 9-10 days of G-CSF treatment following the first cycle of ifosfamide.

AB - The introduction of aggressive chemotherapy in the treatment of osteosarcoma has improved the long-term outcome for these patients. With the increasing aggressiveness of chemotherapy protocols, hematopoietic growth factors have emerged as useful adjuncts involving, in some cases, rescue by peripheral blood stem cell (PBSC) infusion to assist faster recovery and maintain relative dose intensity. To evaluate the number of PBSCs needed, we analyzed the number of CD34+ cells and hematopoietic progenitor cells in the peripheral blood of 16 patients with osteoblastic, condroblastic and fibroblastic osteosarcoma enrolled in an Istituto Ortopedico Rizzoli- Scandinavian Sarcoma Group (IOR-SSG) pilot study, consisting of two cycles of preoperative high dose chemotherapy. The blood samples were studied at different times. The CD34+ cells were analyzed by flow cytometry and the hematopoietic progenitor cells were analyzed by tissue culture clonogenic assay. In comparing the two courses of chemotherapy, we observed that modification of the mean values of WBC, CD34+ and CFU-GM were very similar. The second course of chemotherapy seemed to induce greater hematological toxicity. All three parameters showed good correlation. The results demonstrated that the best time to collect PBSC by means of leukapheresis is post G-CSF used as rescue after ifosfamide treatment. We verified the ability of G-CSF to mobilize PBSCs in patients with osteosarcoma through cytofluorimetric analysis of CD34+ cells and their clonogenic capability. Moreover, during this preoperative treatment, we identified the best time to collect a sufficient number of PBSCs, that is after 9-10 days of G-CSF treatment following the first cycle of ifosfamide.

KW - CD34

KW - Clonogenic cells

KW - Osteosarcoma

KW - Peripheral blood stem cell

UR - http://www.scopus.com/inward/record.url?scp=0032783897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032783897&partnerID=8YFLogxK

M3 - Article

C2 - 10465132

AN - SCOPUS:0032783897

VL - 11

SP - 293

EP - 300

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -